Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger

Showing results (391-400 of 491) with videos related to

Pageof 50
Sort By:
Journal of Hepatology|June 5, 2023
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosisMaria Pilar Ballester, Thomas H Tranah, Lorenz Balcar, et al.
JHEP Reports : Innovation in Hepatology|March 5, 2026
Non-invasive tests to guide hepatocellular carcinoma surveillanceJan Embacher, Katharina Remih, Carolin Victoria Schneider, et al.
Nature Reviews. Gastroenterology & Hepatology|July 17, 2024
A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
Journal of Hepatology|November 2, 2023
Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976]Maria Pilar Ballester, Thomas H Tranah, Lorenz Balcar, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2026
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLDLorenz Balcar, Georg Semmler, Bernhard Scheiner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2025
IgM Antibodies Targeting Malondialdehyde Promote Complement-Mediated Liver Injury in Alcohol-Related Liver DiseaseDragana Rajcic, Beatriz Pereira da Silva, Taras Baranovskyi, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-A prospective biopsy-controlled studyDavid J M Bauer, Larissa Nixdorf, Nina Dominik, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2020
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunctionFrank E Uschner, Kathleen Glückert, Rafael Paternostro, et al.
Hepatology (Baltimore, Md.)|May 16, 2023
Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating eventMarta Tonon, Lorenz Balcar, Georg Semmler, et al.
Pageof 50

Showing results (391-400 of 491) with videos related to

Sort By:
Pageof 50
Journal of Hepatology|June 5, 2023
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosisMaria Pilar Ballester, Thomas H Tranah, Lorenz Balcar, et al.
JHEP Reports : Innovation in Hepatology|March 5, 2026
Non-invasive tests to guide hepatocellular carcinoma surveillanceJan Embacher, Katharina Remih, Carolin Victoria Schneider, et al.
Nature Reviews. Gastroenterology & Hepatology|July 17, 2024
A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
Journal of Hepatology|November 2, 2023
Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976]Maria Pilar Ballester, Thomas H Tranah, Lorenz Balcar, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2026
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLDLorenz Balcar, Georg Semmler, Bernhard Scheiner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2025
IgM Antibodies Targeting Malondialdehyde Promote Complement-Mediated Liver Injury in Alcohol-Related Liver DiseaseDragana Rajcic, Beatriz Pereira da Silva, Taras Baranovskyi, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-A prospective biopsy-controlled studyDavid J M Bauer, Larissa Nixdorf, Nina Dominik, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2020
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunctionFrank E Uschner, Kathleen Glückert, Rafael Paternostro, et al.
Hepatology (Baltimore, Md.)|May 16, 2023
Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating eventMarta Tonon, Lorenz Balcar, Georg Semmler, et al.
Pageof 50